|
Shire Focuses Attention on Underpriced Assets and Adderall XR
As turmoil in the credit markets has limited some companies’ access to capital, the prices of out-licensed drug candidates are falling, making the environment more attractive for pharmaceutical manufacturers with strong cash positions to acquire new products and assets.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives